INTEGRATED BIOPHARMA INC (INBP)

Every figure this model derived for INBP, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2026-03-31.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
capex 187,000 PaymentsToAcquirePropertyPlantAndEquipment 2026-03-31
cash 5,826,000 CashAndCashEquivalentsAtCarryingValue 2026-03-31
current assets 17,974,000 AssetsCurrent 2026-03-31
current liabilities 5,527,000 LiabilitiesCurrent 2026-03-31
equity 18,982,000 StockholdersEquity 2026-03-31
interest expense 121,000 InterestExpenseNonoperating 2026-03-31
ocf 3,026,000 NetCashProvidedByUsedInOperatingActivities 2026-03-31
revenue 48,251,000 RevenueFromContractWithCustomerIncludingAssessedTax 2026-03-31
sbc 185,000 ShareBasedCompensation 2026-03-31

The ratios

The figures themselves rather than their scores — what somebody looking up INBP on one particular measure came for.

RatioValue
cash operating margin-1.59
current ratio3.25
current ratio reported3.25
dilution pct0.96
fcf margin5.88
growth cv9.35
interest cover-10.31
operating margin-2.58
owner earnings margin5.5
revenue growth-8.83
revenue growth per share-9.69
roic-7.42
rule of 40-11.41
sbc pct revenue0.38

What to be careful about

What this model itself distrusts about INBP's figures. Written by the derivation as it ran, not added afterwards.